Cancer radioimmunotherapy

Immunotherapy

Volumn 3, Issue 3, 2011, Pages 349-370

  Sharkey, Robert M ^a   Goldenberg, David M ^a  

^a Garden State Cancer   (United States)

Author keywords

bispecific antibody; cancer; monoclonal antibody; pretargeting; radioimmunotherapy; radionuclide

Indexed keywords

ACTINIUM 225; ANTIBODY; ASTATINE 211; BISMUTH 213; COPPER 67; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IODINE 125; IODINE 131; LUTETIUM 177; RADIOISOTOPE; RHENIUM 188; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; YTTRIUM 90;

CANCER IMMUNOTHERAPY; DRUG RESEARCH; DRUG TARGETING; HUMAN; ISOTOPE LABELING; MOLECULAR BIOLOGY; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SOLID TUMOR;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES;

EID: 79952687471     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.114     Document Type: Review

References (270)

1. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM: Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80(4), 863-878 (1992).
2. Sharkey RM, Burton J, Goldenberg DM: Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal. Expert Rev. Clin. Immunol. 1(1), 47-62 (2005).
3. Sharkey RM, Goldenberg DM: Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 46(Suppl. 1) S115-S127 (2005).
4. Weiner LM, Surana R, Wang S: Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10(5), 317-327 (2010).
5. Nelson AL, Dhimolea E, Reichert JM: Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9(10), 767-774 (2010).
6. Reichert JM: Antibodies to watch in 2010. MAbs 2(1), 84-100 (2010).
7. Pressman D, Korngold L: The in vivo localization of anti-Wagner- osteogenic-sarcoma antibodies. Cancer 6(3), 619-623 (1953).
8. Goldenberg DM, DeLand F, Kim E et al.: Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N. Engl. J. Med. 298(25), 1384-1386 (1978).
9. Goldenberg DM, Sharkey RM: Radioactive antibodies: a historical review of selective targeting and treatment of cancer. Hosp. Pract. 38(4), 82-93 (2010).
10. Goldenberg DM, Gaffar SA, Bennett SJ, Beach JL: Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res. 41(11 Pt 1), 4354-4360 (1981). (Pubitemid 12201340)
11. Order SE, Klein JL, Ettinger D et al.: Phase I-II study of radiolabeled antibody integrated in the treatment of primary hepatic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 6(6), 703-710 (1980). (Pubitemid 10065142)
12. Order SE, Klein JL, Ettinger D et al.: Use of isotopic immunoglobulin in therapy. Cancer Res. 40(8 Pt 2), 3001-3007 (1980).
13. Larson SM, Carrasquillo JA, Krohn KA et al.: Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J. Clin. Invest. 72, 2101-2114 (1983). (Pubitemid 14224416)
14. Gansow OA, Brechbiel MW, Mirzadeh S, Colcher D, Roselli M: Chelates and antibodies: current methods and new directions. Cancer Treat. Res. 51, 153-171 (1990).
15. Moi MK, DeNardo SJ, Meares CF: Stable bifunctional chelates of metals used in radiotherapy. Cancer Res. 50(Suppl. 3), S789-S793 (1990).
16. DeNardo SJ, DeNardo GL, O'Grady LF et al.: Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int. J. Cancer Suppl. 3, 96-101 (1988).
17. DeNardo SJ, DeNardo GL, O'Grady LF et al.: Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int. J. Biol. Markers 2(1), 49-53 (1987).
18. Press OW, Eary JF, Badger CC et al.: Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti- CD37) antibody. J. Clin. Oncol. 7(8), 1027-1038 (1989). (Pubitemid 19196525)
19. Bernstein ID, Eary JF, Badger CC et al.: High dose radiolabeled antibody therapy of lymphoma. Cancer Res. 50(Suppl. 3), S1017-S1021 (1990).
20. Goldenberg DM, Horowitz JA, Sharkey RM et al.: Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J. Clin. Oncol. 9(4), 548-564 (1991).
21. Kaminski MS, Zasadny KR, Francis IR et al.: Radioimmunotherapy of B-cell lymphoma with 131I-anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329(7), 459-465 (1993). (Pubitemid 23222331)
22. Press OW, Eary JF, Appelbaum FR et al.: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329(17), 1219-1224 (1993). (Pubitemid 23306322)
23. Wahl RL: Tositumomab and 131I therapy in non-Hodgkin's lymphoma. J. Nucl. Med. 46(Suppl. 1) S128-S140S (2005).
24. Knox SJ, Goris ML, Trisler K et al.: Yttrium-90- labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res. 2(3), 457-470 (1996). (Pubitemid 26100047)
25. Witzig TE, White CA, Wiseman GA et al.: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 17(12), 3793-3803 (1999).
26. Kaminski MS, Zasadny KR, Francis IR et al.: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 14(7), 1974-1981 (1996). (Pubitemid 26230097)
27. Buchsbaum DJ, Wahl RL, Glenn SD, Normolle DP, Kaminski MS: Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res. 52(3), 637-642 (1992).
28. McLaughlin P, Grillo-Lopez AJ, Link BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16(8), 2825-2833 (1998). (Pubitemid 28363048)
29. Koral KF, Dewaraja Y, Clarke LA et al.: Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non- Hodgkin's lymphoma: preliminary report. Cancer Biother. Radiopharm. 15(4), 347-355 (2000).
30. Sgouros G, Squeri S, Ballangrud AM et al.: Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J. Nucl. Med. 44(2), 260-268 (2003).
31. Sharkey RM, Brenner A, Burton J et al.: Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J. Nucl. Med. 44(12), 2000-2018 (2003). (Pubitemid 40022147)
32. Koral KF, Dewaraja Y, Li J et al.: Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. J. Nucl. Med. 44(3), 457-464 (2003). (Pubitemid 39586025)
33. Dewaraja YK, Schipper MJ, Roberson PL et al.: 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J. Nucl. Med. 51(7), 1155-1162 (2010).
34. Witzig TE, Gordon LI, Cabanillas F et al.: Randomized controlled trial of yttrium-90- labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20(10), 2453-2463 (2002). (Pubitemid 34525730)
35. Davis TA, Kaminski MS, Leonard JP et al.: The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin. Cancer Res. 10(23), 7792-7798 (2004). (Pubitemid 39587516)
36. Cardarelli PM, Quinn M, Buckman D et al.: Binding to CD20 by anti-B1 antibody or F(ab')2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol. Immunother. 51(1), 15-24 (2002). (Pubitemid 34158519)
37. Du Y, Honeychurch J, Cragg MS et al.: Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood 103(4), 1485-1494 (2004). (Pubitemid 38168666)
38. Hernandez MC, Knox SJ: Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 59(5), 1274-1287 (2004). (Pubitemid 38954048)
39. Kapadia NS, Engles JM, Wahl RL: In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. J. Nucl. Med. 49(4), 674-678 (2008). (Pubitemid 351520617)
40. Ivanov A, Krysov S, Cragg MS, Illidge T: Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin. Cancer Res. 14(15), 4925-4934 (2008).
41. Witzig TE, Molina A, Gordon LI et al.: Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium90 ibritumomab tiuxetan. Cancer 109(9), 1804-1810 (2007). (Pubitemid 46668544)
42. Buchegger F, Antonescu C, Delaloye AB et al.: Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br. J. Cancer 94(12), 1770-1776 (2006). (Pubitemid 43882565)
43. Gopal AK, Gooley TA, Maloney DG et al.: High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 102(7), 2351-2357 (2003). (Pubitemid 37193569)
44. Bennett JM, Kaminski MS, Leonard JP et al.: Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 105(12), 4576-4582 (2005). (Pubitemid 40807274)
45. Czuczman MS, Emmanouilides C, Darif M et al.: Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J. Clin. Oncol. 25(27), 4285-4292 (2007). (Pubitemid 47548569)
46. Ansell SM, Schilder RJ, Pieslor PC et al.: Antilymphoma treatments given subsequent to yttrium90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Clin. Lymphoma 5(3), 202-204 (2004). (Pubitemid 40227714)
47. Kaminski MS, Tuck M, Estes J et al.: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. 352(5), 441-449 (2005). (Pubitemid 40175970)
48. Kaminski MS, Estes J, Zasadny KR et al.: Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96(4), 1259-1266 (2000). (Pubitemid 30658452)
49. Kaminski MS, Radford JA, Gregory SA et al.: Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J. Clin. Oncol. 23(31), 7985-7993 (2005). (Pubitemid 46657399)
50. Press OW, Unger JM, Braziel RM et al.: A Phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 102(5), 1606-1612 (2003). (Pubitemid 37022549)
51. Leonard JP, Coleman M, Kostakoglu L et al.: Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I131 tositumomab for untreated follicular lymphoma. J. Clin. Oncol. 23(24), 5696-5704 (2005).
52. Press OW, Unger JM, Braziel RM et al.: Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J. Clin. Oncol. 24(25), 4143-4149 (2006). (Pubitemid 46622291)
53. Morschhauser F, Radford J, Van Hoof A et al.: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J. Clin. Oncol. 26(32), 5156-5164 (2008).
54. Zinzani PL, Tani M, Fanti S et al.: A Phase II trial of CHOP chemotherapy followed by yttrium90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann. Oncol. 19(4), 769-773 (2008). (Pubitemid 351461050)
55. Jacobs SA, Swerdlow SH, Kant J et al.: Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin. Cancer Res. 14(21), 7088-7094 (2008).
56. Zinzani PL, Tani M, Fanti S et al.: A Phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer 112(4), 856-862 (2008). (Pubitemid 351246571)
57. Zinzani PL, Tani M, Pulsoni A et al.: Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a Phase II non-randomised trial (FLUMIZ). Lancet Oncol. 9(4), 352-358 (2008).
58. Morschhauser F, Dreyling M, Rohatiner A, Hagemeister F, Bischof Delaloye A: Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Oncologist 14(Suppl. 2), 17-29 (2009).
59. Hainsworth JD, Spigel DR, Markus TM et al.: Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a Phase II trial of the Sarah Cannon Oncology Research Consortium. Clin. Lymphoma Myeloma 9(3), 223-228 (2009).
60. Alduaij W, Illidge TM: Radioimmunotherapy: strategies for the future in indolent and aggressive lymphoma. Curr. Oncol. Rep. 11(5), 363-370 (2009).
61. Burdick MJ, Neumann D, Pohlman B et al.: External beam radiotherapy followed by 90Y-ibritumomab tiuxetan in relapsed or refractory bulky follicular lymphoma. Int. J. Radiat. Oncol. Biol. Phys. DOI:10.1016/j. ijrobp.2009.12.030 (2010).
62. Link BK, Martin P, Kaminski MS et al.: Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter Phase II study. J. Clin. Oncol. 28(18), 3035-3041 (2010).
63. Zinzani PL, Rossi G, Franceschetti S et al.: Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin. Cancer Res. 16(15), 3998-4004 (2010).
64. Gopal AK, Rajendran JG, Petersdorf SH et al.: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99(9), 3158-3162 (2002). (Pubitemid 34525293)
65. Winter JN: Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. Clin. Lymphoma 5(Suppl. 1), S22-S26 (2004). (Pubitemid 39467702)
66. Vose JM, Bierman PJ, Enke C et al.: Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 23(3), 461-467 (2005). (Pubitemid 46224222)
67. Ferrucci PF, Vanazzi A, Grana CM et al.: High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/ resistant B-cell non-Hodgkin lymphomas. Br. J. Haematol. 139(4), 590-599 (2007). (Pubitemid 350043818)
68. Molina A, Krishnan A, Fung H et al.: Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium90 ibritumomab tiuxetan. Curr. Stem Cell Res. Ther. 2(3), 239-248 (2007). (Pubitemid 47496608)
69. Gopal AK, Rajendran JG, Gooley TA et al.: High-dose 131itositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults ? 60 years old with relapsed or refractory B-cell lymphoma. J. Clin. Oncol. 25(11), 1396-1402 (2007). (Pubitemid 46706888)
70. Krishnan A, Nademanee A, Fung HC et al.: Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 26(1), 90-95 (2008).
71. Shimoni A, Zwas ST, Oksman Y et al.: Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. Bone Marrow Transplant. 41(4), 355-361 (2008). (Pubitemid 351330730)
72. Zhang MM, Gopal AK: Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin. Hematol. 45(2), 118-125 (2008). (Pubitemid 351444840)
73. Devizzi L, Guidetti A, Tarella C et al.: High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J. Clin. Oncol. 26(32), 5175-5182 (2008).
74. Gisselbrecht C, Vose J, Nademanee A, Gianni AM, Nagler A: Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response. Oncologist 14(Suppl. 2), 41-51 (2009).
75. Bethge WA, Lange T, Meisner C et al.: Radioimmunotherapy with yttrium-90- ibritumomab tiuxetan as part of a reduced intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a Phase II study. Blood 116(10), 1795-1802 (2010).
76. Kang BW, Kim WS, Kim C et al.: Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Invest. New Drugs 28(4), 516-522 (2010).
77. Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF: 131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a Phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother. Radiopharm. 18(4), 513-524 (2003). (Pubitemid 37082370)
78. Illidge TM, Bayne M, Brown NS et al.: Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 113(7), 1412-1421 (2009).
79. DeNardo GL, DeNardo SJ, Lamborn KR et al.: Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother. Radiopharm. 13(4), 239-254 (1998). (Pubitemid 28484004)
80. O'Donnell RT, Shen S, Denardo SJ et al.: A Phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. Anticancer Res. 20(5C), 3647-3655 (2000). (Pubitemid 32002254)
81. Matthews DC, Appelbaum FR, Eary JF et al.: Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 94(4), 1237-1247 (1999). (Pubitemid 29380404)
82. Morschhauser F, Kraeber-Bodere F, Wegener WA et al.: High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, Phase I/II study in non-Hodgkin's lymphoma. J. Clin. Oncol. 28(23), 3709-3716 (2010).
83. Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM: Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin. Cancer Res. 14(19), 6154-6160 (2008).
84. Sharkey RM, Press OW, Goldenberg DM: A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood 113(17), 3891-3895 (2009).
85. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM: Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 112(3), 830-835 (2008).
86. Sharkey RM, Karacay H, Johnson CR et al.: Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J. Nucl. Med. 50(3), 444-453 (2009).
87. Jurcic JG, Scheinberg DA: Radioimmunotherapy of hematological cancer: problems and progress. Clin. Cancer Res. 1(12), 1439-1446 (1995). (Pubitemid 26030982)
88. McDevitt MR, Sgouros G, Finn RD et al.: Radioimmunotherapy with a-emitting nuclides. Eur. J. Nucl. Med. 25(9), 1341-1351 (1998).
89. Nikula TK, McDevitt MR, Finn RD et al.: a-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J. Nucl. Med. 40(1), 166-176 (1999). (Pubitemid 29044188)
90. Sgouros G, Ballangrud AM, Jurcic JG et al.: Pharmacokinetics and dosimetry of an a-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J. Nucl. Med. 40(11), 1935-1946 (1999). (Pubitemid 29523591)
91. Jurcic JG, Larson SM, Sgouros G et al.: Targeted a particle immunotherapy for myeloid leukemia. Blood 100(4), 1233-1239 (2002). (Pubitemid 34864277)
92. Zalutsky MR, Pozzi OR: Radioimmunotherapy with a-particle emitting radionuclides. Q. J. Nucl. Med. Mol. Imaging 48(4), 289-296 (2004).
93. Mulford DA, Scheinberg DA, Jurcic JG: The promise of targeted a-particle therapy. J. Nucl. Med. 46(Suppl. 1) S199-S204 (2005).
94. McDevitt MR, Ma D, Lai LT et al.: Tumor therapy with targeted atomic nanogenerators. Science 294 (5546), 1537-1540 (2001). (Pubitemid 33063927)
95. Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA: Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 63(16), 5084-5090 (2003). (Pubitemid 37022648)
96. Yao Z, Zhang M, Garmestani K et al.: Pretargeted a emitting radioimmunotherapy using 213Bi 1,4,7,10-tetraazacyclododecane- N,N',N'',N'''-tetraacetic acid-biotin. Clin. Cancer Res. 10(9), 3137-3146 (2004). (Pubitemid 38619695)
97. Jaggi JS, Seshan SV, McDevitt MR et al.: Renal tubulointerstitial changes after internal irradiation with a-particle-emitting actinium daughters. J. Am. Soc. Nephrol. 16(9), 2677-2689 (2005).
98. Jaggi JS, Seshan SV, McDevitt MR et al.: Mitigation of radiation nephropathy after internal a-particle irradiation of kidneys. Int. J. Radiat. Oncol. Biol. Phys. 64(5), 1503-1512 (2006).
99. Sofou S, Kappel BJ, Jaggi JS et al.: Enhanced retention of the a-particle-emitting daughters of actinium-225 by liposome carriers. Bioconjug. Chem. 18(6), 2061-2067 (2007). (Pubitemid 350220009)
100. Miederer M, Scheinberg DA, McDevitt MR: Realizing the potential of the actinium-225 radionuclide generator in targeted a particle therapy applications. Adv. Drug Deliv. Rev. 60(12), 1371-1382 (2008).
101. Song H, Hobbs RF, Vajravelu R et al.: Radioimmunotherapy of breast cancer metastases with a-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res. 69(23), 8941-8948 (2009).
102. Senekowitsch-Schmidtke R, Schuhmacher C, Becker KF et al.: Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional a-radioimmunotherapy of diffuse-type gastric cancer. Cancer Res. 61(7), 2804-2808 (2001). (Pubitemid 32691914)
103. Elgqvist J, Andersson H, Back T et al.: Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. J. Nucl. Med. 46(11), 1907-1915 (2005). (Pubitemid 46196654)
104. Zalutsky MR: Current status of therapy of solid tumors: brain tumor therapy. J. Nucl. Med. 46(Suppl. 1), S151-S156 (2005).
105. Andersson H, Cederkrantz E, Back T et al.: Intraperitoneal a-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-MX35 F(ab')2 - a Phase I study. J. Nucl. Med. 50(7), 1153-1160 (2009).
106. Zalutsky MR, Reardon DA, Akabani G et al.: Clinical experience with a-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J. Nucl. Med. 49(1), 30-38 (2008).
107. Singh Jaggi J, Henke E, Seshan SV et al.: Selective a-particle mediated depletion of tumor vasculature with vascular normalization. PLoS One 2(3), E267 (2007).
108. Kennel SJ, Chappell LL, Dadachova K et al.: Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors. Cancer Biother. Radiopharm. 15(3), 235-244 (2000). (Pubitemid 30612706)
109. Kennel SJ, Mirzadeh S, Eckelman WC et al.: Vascular-targeted radioimmunotherapy with the a-particle emitter 211At. Radiat. Res. 157(6), 633-641 (2002). (Pubitemid 34569130)
110. Kennel SJ, Huang Y, Zeng WB, Stuckey A, Wall J: Kinetics of vascular targeted monoclonal antibody. Curr. Drug. Deliv. 7(5), 428-435 (2010).
111. Zhu X, Palmer MR, Makrigiorgos GM, Kassis AI: Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis. Med. Phys. 37(6), 2974-2984 (2010).
112. Mattes MJ: The mechanism of killing of B-lymphoma cells by 111In-conjugated antibodies. Int. J. Radiat. Biol. 84(5), 389-399 (2008). (Pubitemid 351878842)
113. Mattes MJ: Radionuclide-antibody conjugates for single-cell cytotoxicity. Cancer 94(Suppl. 4), 1215-1223 (2002). (Pubitemid 34150881)
114. Ong GL, Elsamra SE, Goldenberg DM, Mattes MJ: Single-cell cytotoxicity with radiolabeled antibodies. Clin. Cancer Res. 7(1), 192-201 (2001). (Pubitemid 32110223)
115. Michel RB, Brechbiel MW, Mattes MJ: A comparison of 4 radionuclides conjugated to antibodies for single-cell kill. J. Nucl. Med. 44(4), 632-640 (2003). (Pubitemid 39663432)
116. Mattes MJ, Goldenberg DM: Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electrons. Eur. J. Nucl. Med. Mol. Imaging 35(7), 1249-1258 (2008).
117. Tempero M, Leichner P, Dalrymple G et al.: High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a Phase I trial. J. Clin. Oncol. 15(4), 1518-1528 (1997). (Pubitemid 27167388)
118. Wong JYC, Chu DZ, Yamauchi DM et al.: A Phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin. Cancer Res. 6(10), 3855-3863 (2000).
119. Tempero M, Leichner P, Baranowska-Kortylewicz J et al.: High-dose therapy with 90yttrium-labeled monoclonal antibody CC49: a Phase I trial. Clin. Cancer Res. 6(8), 3095-3102 (2000). (Pubitemid 30637733)
120. Wong JY, Shibata S, Williams LE et al.: A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin. Cancer Res. 9(16 Pt 1), 5842-5852 (2003). (Pubitemid 38018066)
121. Tagawa ST, Beltran H, Vallabhajosula S et al.: Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 116(Suppl. 4), 1075-1083 (2010).
122. Epenetos AA, Hird V, Lambert H, Mason P, Coulter C: Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int. J. Gynecol. Cancer 10(Suppl. 1), 44-46 (2000). (Pubitemid 30220628)
123. Verheijen RH, Massuger LF, Benigno BB et al.: Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J. Clin. Oncol. 24(4), 571-578 (2006). (Pubitemid 46655592)
124. Chen S, Yu L, Jiang C et al.: Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J. Clin. Oncol. 23(7), 1538-1547 (2005).
125. Shapiro WR, Carpenter SP, Roberts K, Shan JS: 131I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma. Expert Opin. Biol. Ther. 6(5), 539-545 (2006). (Pubitemid 43723302)
126. Street HH, Goris ML, Fisher GA et al.: Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. Cancer Biother. Radiopharm. 21(3), 243-256 (2006). (Pubitemid 44115194)
127. Shapiro WR, Judy K, Patel SJ et al.: Open-label, dose confirmation, and dosimetry study of interstitial 131I-chTNT-1/B MAb for the treatment of recurrent glioblastoma multiforme (GBM): final results. J. Clin. Oncol. 28(Suppl. 15), Abstract 2039 (2010).
128. Milenic DE, Wong KJ, Baidoo KE et al.: Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother. Radiopharm. 23(5), 619-631 (2008).
129. Niu G, Sun X, Cao Q et al.: Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin. Cancer Res. 16(7), 2095-2105 (2010).
130. Rades D, Wolff C, Nadrowitz R et al.: Radioactive EGFR antibody cetuximab in multimodal cancer treatment: stability and synergistic effects with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 75(4), 1226-1231 (2009).
131. Tijink BM, Laeremans T, Budde M et al.: Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular nanobody technology. Mol. Cancer Ther. 7(8), 2288-2297 (2008).
132. Tijink BM, Neri D, Leemans CR et al.: Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J. Nucl. Med. 47(7), 1127-1135 (2006). (Pubitemid 47544908)
133. Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM: 111In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J. Nucl. Med. 48(8), 1357-1368 (2007). (Pubitemid 47242802)
134. Palm S, Enmon RM, Jr., Matei C et al.: Pharmacokinetics and biodistribution of 86Y-trastuzumab for 90Y dosimetry in an ovarian carcinoma model: correlative MicroPET, MRI. J. Nucl. Med. 44(7), 1148-1155 (2003). (Pubitemid 39663389)
135. Tolmachev V, Orlova A, Pehrson R et al.: Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 67(6), 2773-2782 (2007). (Pubitemid 46548966)
136. Milenic DE, Wong KJ, Baidoo KE et al.: Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. MAbs 2(5), 550-564 (2010).
137. Wong JY, Raubitschek A, Yamauchi D et al.: A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. Cancer Biother. Radiopharm. 25(4), 387-394 (2010).
138. Boskovitz A, McLendon RE, Okamura T et al.: Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of a-particle-emitting 211At-labeled trastuzumab. Nucl. Med. Biol. 36(6), 659-669 (2009).
139. Krop IE, Beeram M, Modi S et al.: Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28(16), 2698-2704 (2010).
140. Liu Z, Liu Y, Jia B et al.: Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab. Mol. Cancer Ther. 9(8), 2297-2308 (2010).
141. Hecht JR, Mitchell E, Neubauer MA et al.: Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin. Cancer Res. 16(7), 2205-2213 (2010).
142. Meredith RF, Khazaeli MB, Plott WE et al.: Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin. Cancer Res. 2(11), 1811-1818 (1996). (Pubitemid 26384146)
143. Pagel JM, Pantelias A, Hedin N et al.: Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. Cancer Res. 67(12), 5921-5928 (2007). (Pubitemid 46985028)
144. Buchegger F, Roth A, Allal A et al.: Radioimmunotherapy of colorectal cancer liver metastases: combination with radiotherapy. Ann. NY Acad. Sci. 910, 263-269; discussion 269-270 (2000).
145. Kinuya S, Yokoyama K, Hiramatsu T et al.: Optimal timing of administration of hyperthermia in combined radioimmunotherapy. Cancer Biother. Radiopharm. 15(4), 373-379 (2000).
146. Li XF, Kinuya S, Yokoyama K et al.: Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells. Eur. J. Nucl. Med. Mol. Imaging 29(12), 1669-1674 (2002).
147. Pallela VR, Rao SP, Thakur ML: Interferon-a-2b immunoconjugate for improving immunoscintigraphy and immunotherapy. J. Nucl. Med. 41(6), 1108-1113 (2000). (Pubitemid 30396666)
148. Pedley RB, El-Emir E, Flynn AA et al.: Synergy between vascular targeting agents and antibody-directed therapy. Int. J. Radiat. Oncol. Biol. Phys. 54(5), 1524-1531 (2002). (Pubitemid 35380059)
149. Kraeber-Bodere F, Bodet-Milin C, Niaudet C et al.: Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft. J. Nucl. Med. 51(4), 624-631 (2010).
150. Meyer T, Gaya AM, Dancey G et al.: A Phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin. Cancer Res. 15(13), 4484-4492 (2009).
151. Sharkey RM, Goldenberg DM: Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv. Drug Deliv. Rev. 60(12), 1407-1420 (2008).
152. Rowlinson G, Snook D, Busza A, Epenetos AA: Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous antibody administration. Cancer Res. 47(24 Pt 1), 6528-6531 (1987). (Pubitemid 18019649)
153. Wahl RL, Barrett J, Geatti O et al.: The intraperitoneal delivery of radiolabeled monoclonal antibodies: studies on the regional delivery advantage. Cancer Immunol. Immunother. 26(3), 187-201 (1988).
154. Colcher D, Esteban J, Carrasquillo JA et al.: Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res. 47(15), 4218-4224 (1987). (Pubitemid 17108496)
155. Alvarez RD, Partridge EE, Khazaeli MB et al.: Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a Phase I/II study. Gynecol. Oncol. 65(1), 94-101 (1997). (Pubitemid 27171559)
156. Meredith RF, Khazaeli MB, Macey DJ et al.: Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin. Cancer Res. 5(Suppl. 10), S3254-S3258 (1999).
157. Oei AL, Verheijen RH, Seiden MV et al.: Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int. J. Cancer 120(12), 2710-2714 (2007). (Pubitemid 46651295)
158. Andersson H, Elgqvist J, Horvath G et al.: Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin. Cancer Res. 9(10 Pt 2), S3914-S3921S (2003).
159. Elgqvist J, Andersson H, Back T et al.: Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity. Nucl. Med. Biol. 33(8), 1065-1072 (2006). (Pubitemid 44791950)
160. Elgqvist J, Johansson BR, Partheen K, Danielsson A: Tumor cure probability during a-RIT of ovarian cancer with different radiation sensitivity. Anticancer Res. 30(7), 2545-2551 (2010).
161. Milenic DE, Garmestani K, Brady ED et al.: a-particle radioimmunotherapy of disseminated peritoneal disease using a 212Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother. Radiopharm. 20(5), 557-568 (2005). (Pubitemid 41619147)
162. Aarts F, Bleichrodt RP, Oyen WJ, Boerman OC: Intracavitary radioimmunotherapy to treat solid tumors. Cancer Biother. Radiopharm. 23(1), 92-107 (2008). (Pubitemid 351304213)
163. Reardon DA, Akabani G, Coleman RE et al.: Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 20(5), 1389-1397 (2002). (Pubitemid 34177447)
164. Reardon DA, Akabani G, Coleman RE et al.: Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. J. Clin. Oncol. 24(1), 115-122 (2006). (Pubitemid 46630502)
165. Reardon DA, Quinn JA, Akabani G et al.: Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: Phase I trial results. J. Nucl. Med. 47(6), 912-918 (2006). (Pubitemid 46939942)
166. McLendon RE, Akabani G, Friedman HS et al.: Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl. Med. Biol. 34(4), 405-413 (2007). (Pubitemid 46710405)
167. Akabani G, Cokgor I, Coleman RE et al.: Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int. J. Radiat. Oncol. Biol. Phys. 46(4), 947-958 (2000). (Pubitemid 30114408)
168. Reardon DA, Zalutsky MR, Akabani G et al.: A pilot study: 131I-antitenascin monoclonal antibody 81C6 to deliver a 44-Gy resection cavity boost. Neuro Oncol. 10(2), 182-189 (2008).
169. Zalutsky MR, Reardon DA, Pozzi OR, Vaidyanathan G, Bigner DD: Targeted a-particle radiotherapy with 211At-labeled monoclonal antibodies. Nucl. Med. Biol. 34(7), 779-785 (2007). (Pubitemid 47505399)
170. Casaco A, Lopez G, Garcia I et al.: Phase I single-dose study of intracavitary-administered nimotuzumab labeled with 188Re in adult recurrent high-grade glioma. Cancer Biol. Ther. 7(3), 333-339 (2008). (Pubitemid 351847044)
171. Kramer K, Kushner BH, Modak S et al.: Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J. Neurooncol. 97(3), 409-418 (2010).
172. Iwamoto FM, Schwartz J, Pandit-Taskar N et al.: Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer 110(11), 2528-2534 (2007). (Pubitemid 350174940)
173. Kramer K, Humm JL, Souweidane MM et al.: Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J. Clin. Oncol. 25(34), 5465-5470 (2007). (Pubitemid 350232224)
174. Maza S, Kiewe P, Munz DL et al.: First report on a prospective trial with yttrium-90- labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro. Oncol. 11(4), 423-429 (2009).
175. Doolittle ND, Jahnke K, Belanger R et al.: Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk. Lymphoma 48(9), 1712-1720 (2007). (Pubitemid 47386706)
176. Quang TS, Brady LW: Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int. J. Radiat. Oncol. Biol. Phys. 58(3), 972-975 (2004). (Pubitemid 38221158)
177. Li L, Quang TS, Gracely EJ et al.: A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J. Neurosurg. 113(2), 192-198 (2010).
178. Stupp R, Mason WP, van den Bent MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005). (Pubitemid 40349501)
179. Moustakas A, Kreisl TN: New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. Onco. Targets Ther. 3, 27-38 (2010).
180. Blumenthal RD, Sharkey RM, Haywood L et al.: Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies. Cancer Res. 52(21), 6036-6044 (1992).
181. Boerman OC, Sharkey RM, Blumenthal RD, Aninipot RL, Goldenberg DM: The presence of a concomitant bulky tumor can decrease the uptake and therapeutic efficacy of radiolabeled antibodies in small tumors. Int. J. Cancer 51(3), 470-475 (1992).
182. Liersch T, Meller J, Kulle B et al.: Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J. Clin. Oncol. 23(27), 6763-6770 (2005). (Pubitemid 46190272)
183. Liersch T, Meller J, Bittrich M et al.: Update of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann. Surg. Oncol. 14(9), 2577-2590 (2007). (Pubitemid 47389553)
184. DeNardo SJ, Kukis DL, Kroger LA et al.: Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc. Natl Acad. Sci. USA 94(8), 4000-4004 (1997). (Pubitemid 27180488)
185. Kelly MP, Lee FT, Tahtis K et al.: Radioimmunotherapy with a-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy. Clin. Cancer Res. 13(18 Pt 2), S5604-S5612 (2007).
186. Milenic DE, Garmestani K, Brady ED et al.: Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin. Cancer Res. 13(6), 1926-1935 (2007). (Pubitemid 46957364)
187. Costantini DL, Bateman K, McLarty K, Vallis KA, Reilly RM: Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate. J. Nucl. Med. 49(9), 1498-1505 (2008).
188. Al-Ejeh F, Darby JM, Brown MP: Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors. PLoS One 4(2), E4630 (2009).
189. Kelly MP, Lee ST, Lee FT et al.: Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate 69(1), 92-104 (2009).
190. Blumenthal RD, Leone E, Goldenberg DM: Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy. Anticancer Res. 23(6C), 4613-4619 (2003). (Pubitemid 38173875)
191. DeNardo SJ, Kroger LA, Lamborn KR et al.: Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer 80(Suppl. 12), 2583-2590 (1997). (Pubitemid 28009515)
192. Panjideh H, Da Silva Coelho VC, Dernedde J et al.: Biodistribution and efficacy of 131I-A33scFv::CDy, a recombinant antibody-enzyme protein for colon cancer. Int. J. Oncol. 32(4), 925-930 (2008). (Pubitemid 351780603)
193. Karacay H, Govindan SV, Sharkey RM, Goldenberg DM: Combining antibody-targeted radiation (radioimmunotherapy) and antibody-SN-38 conjugates (ADC) improves pancreatic cancer therapy. Proc. Am. Assoc. Cancer Res. Abstract 5543 (2010).
194. Sharkey RM, Hajjar G, Yeldell D et al.: A Phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J. Nucl. Med. 46(4), 620-633 (2005). (Pubitemid 41716407)
195. Forero A, Meredith RF, Khazaeli MB et al.: Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration. Cancer Biother. Radiopharm. 20(5), 467-478 (2005). (Pubitemid 41619138)
196. Richman CM, DeNardo SJ, O'Donnell RT et al.: High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin. Cancer Res. 11(16), 5920-5927 (2005). (Pubitemid 41170321)
197. Pennington K, Guarion MJ, Serafini AN et al.: Multicenter study of radiosensitizing gemcitabine combined with fractionated radioimmunotherapy for repeated treatment cycles in advanced pancreatic cancer. J. Clin. Oncol. 27(Suppl. 15), 231 Abstract 4620 (2009).
198. Pennington KL, Guarion MJ, Sheikh A et al.: Repeated treatment cycles of fractionated radioimmunotherapy (RAIT) combined with low-dose radiosensitizing gemcitabine (Gem) in advanced pancreatic cancer (APC). Presented at: 2010 Gastrointestinal Cancer Symposium. Orlando, FL, USA, 22-24 January 2010.
199. Gulec AA, Cohen SJ, Pennington KL et al.: Treatment of advanced pancreatic carcinoma with 90Y-clivatuzumab tetraxetan (humanized anti-pancreatic mucin antibody, hPAM4): a Phase I dose escalation trial. Clin. Cancer Res. (2011) (In press).
200. Colcher D, Pavlinkova G, Beresford G et al.: Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q. J. Nucl. Med. 42(4), 225-241 (1998). (Pubitemid 29052423)
201. Milenic DE, Yokota T, Filpula DR et al.: Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 51(23 Pt 1), 6363-6371 (1991).
202. Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM: Biodistribution and radiation dose estimates for yttrium-and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res. 50(8), 2330-2336 (1990). (Pubitemid 20134490)
203. Baxter LT, Jain RK: Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc. Res. 40(2), 246-263 (1990). (Pubitemid 20327678)
204. Baxter LT, Jain RK: Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc. Res. 41(1), 5-23 (1991).
205. Primus FJ, Wang RH, Goldenberg DM, Hansen HJ: Localization of human GW-39 tumors in hamsters by radiolabeled heterospecific antibody to carcinoembryonic antigen. Cancer Res. 33(11), 2977-2982 (1973).
206. Fujimori K, Covell DG, Fletcher JE, Weinstein JN: Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res. 49(20), 5656-5663 (1989). (Pubitemid 19256448)
207. Weinstein JN, van Osdol W: Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the 'binding site barrier'. Cancer Res. 52(Suppl. 9), S2747-S2751 (1992).
208. Rudnick SI, Adams GP: Affinity and avidity in antibody-based tumor targeting. Cancer Biother. Radiopharm. 24(2), 155-161 (2009).
209. Schlom J, Eggensperger D, Colcher D et al.: Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res. 52(5), 1067-1072 (1992).
210. Blumenthal RD, Fand I, Sharkey RM et al.: The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study. Cancer Immunol. Immunother. 33(6), 351-358 (1991).
211. Boerman OC, Sharkey RM, Wong GY et al.: Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor. Cancer Immunol. Immunother. 35(2), 127-134 (1992).
212. Goldenberg DM, Sharkey RM, Ford E: Anti-antibody enhancement of iodine-131 anti-CEA radioimmunodetection in experimental and clinical studies. J. Nucl. Med. 28(10), 1604-1610 (1987). (Pubitemid 17158135)
213. Martensson L, Nilsson R, Ohlsson T et al.: Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion. J. Nucl. Med. 48(2), 269-276 (2007). (Pubitemid 47555354)
214. Colcher D, Goel A, Pavlinkova G et al.: Effects of genetic engineering on the pharmacokinetics of antibodies. Q. J. Nucl. Med. 43(2), 132-139 (1999). (Pubitemid 29318048)
215. Olafsen T, Wu AM: Antibody vectors for imaging. Semin. Nucl. Med. 40(3), 167-181 (2010).
216. Olafsen T, Kenanova VE, Wu AM: Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat. Protoc. 1(4), 2048-2060 (2006). (Pubitemid 46773329)
217. Behr TM, Memtsoudis S, Sharkey RM et al.: Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int. J. Cancer 77(5), 787-795 (1998). (Pubitemid 28341398)
218. Slavin-Chiorini DC, Kashmiri SV, Schlom J et al.: Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res. 55(Suppl. 23), S5957-S5967 (1995).
219. Behr TM, Sharkey RM, Sgouros G et al.: Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer 80(Suppl. 12), 2591-2610 (1997). (Pubitemid 28009516)
220. Vegt E, de Jong M, Wetzels JF et al.: Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J. Nucl. Med. 51(7), 1049-1058 (2010).
221. Geerlings MW: Radionuclides for radioimmunotherapy: criteria for selection. Int. J. Biol. Markers 8(3), 180-186 (1993). (Pubitemid 23329600)
222. Mausner LF, Srivastava SC: Selection of radionuclides for radioimmunotherapy. Med. Phys. 20(2 Pt 2), 503-509 (1993).
223. Stein R, Govindan SV, Mattes MJ et al.: Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res. 63(1), 111-118 (2003). (Pubitemid 36070428)
224. Reardan DT, Meares CF, Goodwin DA et al.: Antibodies against metal chelates. Nature 316(6025), 265-268 (1985). (Pubitemid 15073694)
225. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J: In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J. Nucl. Med. 30(8), 1358-1366 (1989). (Pubitemid 19190299)
226. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF: Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 24(5), 823-834 (2006). (Pubitemid 46671186)
227. Hnatowich DJ, Virzi F, Rusckowski M: Investigations of avidin and biotin for imaging applications. J. Nucl. Med. 28(8), 1294-1302 (1987). (Pubitemid 17156417)
228. Axworthy DB, Reno JM, Hylarides MD et al.: Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl Acad. Sci. USA 97(4), 1802-1807 (2000). (Pubitemid 30118523)
229. Breitz HB, Weiden PL, Beaumier PL et al.: Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. J. Nucl. Med. 41(1), 131-140 (2000). (Pubitemid 30046695)
230. Knox SJ, Goris ML, Tempero M et al.: Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res. 6(2), 406-414 (2000). (Pubitemid 30111457)
231. Schultz J, Lin Y, Sanderson J et al.: A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res. 60(23), 6663-6669 (2000).
232. Paganelli G, Malcovati M, Fazio F: Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin system. International Workshop on Techniques for Amplification of Tumour Targetting. Nucl. Med. Commun. 12(3), 211-234 (1991).
233. Goldenberg DM, Chang CH, Sharkey RM et al.: Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur. J. Nucl. Med. Mol. Imaging 30(5), 777-780 (2003).
234. Paganelli G, Chinol M: Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur. J. Nucl. Med. Mol. Imaging 30(5), 773-776 (2003). (Pubitemid 36612961)
235. Liu G, Dou S, Mardirossian G et al.: Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue. Clin. Cancer Res. 12(16), 4958-4964 (2006). (Pubitemid 44338584)
236. Liu G, Dou S, Pretorius PH et al.: Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF. Eur. J. Nucl. Med. Mol. Imaging 35(2), 272-280 (2008).
237. Pagel JM, Orgun N, Hamlin DK et al.: A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood 113(20), 4903-4913 (2009).
238. Karacay H, Sharkey RM, Rossi EA et al.: A new tri-Fab recombinant bispecific antibody (bsMAb) for pretargeting epithelial cancers: studies with TF12 and 111In-labeled hapten-peptide (IMP 288) in ovarian cancer. J. Nucl. Med. 51(Suppl. 2), Abstract 1148 (2010).
239. Karacay H, McBride WJ, Griffiths GL et al.: Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a 99mTc-/188Re-labeled peptide. Bioconjug. Chem. 11(6), 842-854 (2000).
240. McBride WJ, Zanzonico P, Sharkey RM et al.: Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J. Nucl. Med. 47(10), 1678-1688 (2006). (Pubitemid 47545036)
241. Janevik-Ivanovska E, Gautherot E, Hillairet de Boisferon M et al.: Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconjug. Chem. 8(4), 526-533 (1997). (Pubitemid 27347560)
242. McBride WJ, D'Souza CA, Sharkey RM et al.: Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug. Chem. 21(7), 1331-1340 (2010).
243. Schoffelen R, Sharkey RM, Goldenberg DM et al.: Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol. Cancer Ther. 9(4), 1019-1027 (2010).
244. Sharkey RM, Cardillo TM, Rossi EA et al.: Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat. Med. 11(11), 1250-1255 (2005). (Pubitemid 43093674)
245. Sharkey RM, Karacay H, Vallabhajosula S et al.: Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT, PET in a mouse model. Radiology 246(2), 497-507 (2008).
246. Karacay H, Brard PY, Sharkey RM et al.: Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin. Cancer Res. 11(21), 7879-7885 (2005). (Pubitemid 41611634)
247. Kraeber-Bodere F, Sai-Maurel C, Campion L et al.: Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol. Cancer Ther. 1(4), 267-274 (2002).
248. Graves SS, Dearstyne E, Lin Y et al.: Combination therapy with pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin. Cancer Res. 9 (10 Pt 1), 3712-3721 (2003). (Pubitemid 37169240)
249. Karacay H, Sharkey RM, Gold DV et al.: Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine. J. Nucl. Med. 50(12), 2008-2016 (2009).
250. Shen S, Forero A, LoBuglio AF et al.: Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J. Nucl. Med. 46(4), 642-651 (2005). (Pubitemid 41716409)
251. Kraeber-Bodere F, Rousseau C, Bodet- Milin C et al.: Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a Phase I optimization clinical trial. J. Nucl. Med. 47(2), 247-255 (2006). (Pubitemid 46780889)
252. Paganelli G, Grana C, Chinol M et al.: Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur. J. Nucl. Med. 26(4), 348-357 (1999). (Pubitemid 29176445)
253. Grana C, Chinol M, Robertson C et al.: Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br. J. Cancer 86(2), 207-212 (2002). (Pubitemid 34185147)
254. Mirallie E, Vuillez JP, Bardet S et al.: High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J. Clin. Endocrinol. Metab. 90(2), 779-788 (2005). (Pubitemid 40279196)
255. Chatal JF, Campion L, Kraeber-Bodere F et al.: Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J. Clin. Oncol. 24(11), 1705-1711 (2006). (Pubitemid 46622142)
256. Paganelli G, Bartolomei M, Ferrari M et al.: Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: Phase I study and preliminary therapeutic results. Cancer Biother. Radiopharm. 16(3), 227-235 (2001). (Pubitemid 32641220)
257. Forero A, Weiden PL, Vose JM et al.: Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 104(1), 227-236 (2004). (Pubitemid 38879862)
258. Green DJ, Pagel JM, Nemecek ER et al.: Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. Blood 114(6), 1226-1235 (2009).
259. Rossi EA, Goldenberg DM, Cardillo TM et al.: Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc. Natl Acad. Sci. USA 103(18), 6841-6846 (2006).
260. Schoffelen R, Franssen G, McBride WJ et al.: Pretargeted immunoPET for imaging human colonic cancer in a mouse model. J. Nucl. Med. 51(Suppl. 2), Abstract 61 (2010).
261. Sharkey RM, Karacay H, Litwin S et al.: Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res. 68(13), 5282-5290 (2008).
262. Sharkey RM, Rossi EA, McBride WJ, Chang CH, Goldenberg DM: Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin. Nucl. Med. 40(3), 190-203 (2010).
263. Dadachova E, Wang XG, Casadevall A: Targeting the virus with radioimmunotherapy in virus-associated cancers. Cancer Biother. Radiopharm. 22(3), 303-308 (2007). (Pubitemid 47067888)
264. Dadachova E: Radioimmunotherapy of infection with Bi-labeled antibodies. Curr. Radiopharm. 1(3), 234-239 (2008).
265. Dadachova E, Casadevall A: Host and microbial cells as targets for armed antibodies in the treatment of infectious diseases. Curr. Opin. Investig. Drugs 9(2), 184-188 (2008). (Pubitemid 351206377)
266. Bryan RA, Jiang Z, Huang X et al.: Radioimmunotherapy is effective against high-inoculum Cryptococcus neoformans infection in mice and does not select for radiation-resistant cryptococcal cells. Antimicrob. Agents Chemother. 53(4), 1679-1682 (2009).
267. Rivera J, Nakouzi AS, Morgenstern A et al.: Radiolabeled antibodies to Bacillus anthracis toxins are bactericidal and partially therapeutic in experimental murine anthrax. Antimicrob. Agents Chemother. 53(11), 4860-4868 (2009).
268. Dadachova E, Casadevall A: Radioimmunotherapy of infectious diseases. Semin. Nucl. Med. 39(2), 146-153 (2009).
269. Bryan RA, Jiang Z, Howell RC et al.: Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection. J. Infect. Dis. 202(4), 633-637 (2010).
270. Kassis AI: Therapeutic radionuclides: biophysical and radiobiologic principles. Semin. Nucl. Med. 38(5), 358-366 (2008). (Pubitemid 352033559)